Panic Disorder
📧 Sign up to get email alerts when something new happens for Panic Disorder.
Sign up freeTop drugs studied for this disease
-
FDA label_change · 2021-09-20FDA Approved: ZOLOFT — Supplemental Application (ROERIG)
FDA approved a supplemental application for Zoloft (sertraline hydrochloride) submitted by Roerig to update the product labeling.
-
FDA approval · 2021-09-20FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Dr. Reddy's Laboratories Limited)
FDA approved a supplemental application for venlafaxine hydrochloride from Dr. Reddy's Laboratories Limited.
-
FDA approval · 2021-09-20FDA Approved: FLUOXETINE — Supplemental Application (Saptalis Pharmaceuticals, LLC.)
The FDA approved a supplemental application for fluoxetine from Saptalis Pharmaceuticals, LLC., enabling a generic fluoxetine product under …
-
FDA approval · 2021-09-20FDA Approved: FLUOXETINE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for fluoxetine from Aurobindo Pharma Limited, granting approval of a generic fluoxetine product.
-
FDA approval · 2021-09-20FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Vertical Pharmaceuticals, LLC)
The FDA approved a supplemental application for Venlafaxine hydrochloride from Vertical Pharmaceuticals, LLC.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA label_change · 2021-09-20FDA Approved: VENLAFAXINE — Supplemental Application (Alembic Pharmaceuticals Inc.)
FDA notice of a supplemental labeling application for VENLAFAXINE by Alembic Pharmaceuticals Inc.
-
FDA approval · 2021-09-20FDA Approved: FLUOXETINE HYDROCHLORIDE — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals' supplemental application for fluoxetine hydrochloride, enabling marketing of a generic fluoxetine produc…
-
FDA label_change · 2021-09-15FDA Approved: ALPRAZOLAM — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for Alprazolam submitted by Sandoz Inc, resulting in changes to the product labeling.
-
FDA approval · 2021-09-03FDA Approved: VENLAFAXINE — Supplemental Application (Cadila Pharmaceuticals Limited)
FDA approved a supplemental application for Venlafaxine from Cadila Pharmaceuticals Limited.
-
FDA approval · 2021-09-03FDA Approved: VENLAFAXINE — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
FDA approved a supplemental application for venlafaxine (generic) from Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc., approv…
-
FDA approval · 2021-09-03FDA Approved: PAROXETINE — Original Application (ANI Pharmaceuticals, Inc.)
ANI Pharmaceuticals received FDA approval for an original ANDA application for paroxetine, a generic antidepressant.
-
FDA approval · 2021-09-02FDA Approved: VENLAFAXINE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for venlafaxine by Sun Pharmaceutical Industries, Inc.
-
FDA approval · 2021-09-01FDA Approved: FLUOXETINE HYDROCHLORIDE — Supplemental Application (Dr.Reddy's Laboratories Limited)
FDA approved a supplemental application for fluoxetine hydrochloride from Dr. Reddy's Laboratories Limited (ANDA 078572), updating regulator…
-
FDA approval · 2021-08-31FDA Approved: FLUOXETINE — Supplemental Application (Saptalis Pharmaceuticals, LLC.)
FDA approved a supplemental application for fluoxetine from Saptalis Pharmaceuticals, confirming the availability of a generic fluoxetine pr…
-
FDA approval · 2021-08-27FDA Approved: FLUOXETINE — Supplemental Application (PAI Holdings, LLC dba PAI Pharma)
FDA approved a supplemental application for a fluoxetine hydrochloride generic product from PAI Holdings (PAI Pharma). This action approves …
-
FDA approval · 2021-08-27FDA Approved: PAROXETINE — Original Application (Modavar Pharmaceuticals LLC)
FDA approved a generic paroxetine tablet product from Modavar Pharmaceuticals LLC under an original abbreviated new drug application (ANDA 2…
-
FDA approval · 2021-08-25FDA Approved: FLUOXETINE — Supplemental Application (Dr.Reddy's Laboratories Limited)
The FDA approved a supplemental application for Fluoxetine from Dr. Reddy's Laboratories Limited.
-
FDA approval · 2021-08-06FDA Approved: VENLAFAXINE HYDROCHLORIDE — Original Application (Epic Pharma, LLC)
FDA approved the original application for Venlafaxine hydrochloride (generic) manufactured by Epic Pharma, LLC.
-
CLINICAL_TRIALS trial_result · 2021-07-02Clinical Trial Update: The Role of Orexin in Human Panic Disorder [Phase 4]
Phase 4 clinical trial investigating the role of orexin in panic disorder has completed, with results posted.
-
FDA approval · 2021-06-30FDA Approved: VENLAFAXINE — Original Application (Dr. Reddy's Laboratories Inc.)
FDA approved the original application for venlafaxine from Dr. Reddy's Laboratories, making a generic version of the antidepressant availabl…
-
FDA approval · 2021-06-16FDA Approved: ALPRAZOLAM — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for Alprazolam from Hikma Pharmaceuticals USA Inc. (generic alprazolam).
-
FDA approval · 2021-06-10FDA Approved: VENLAFAXINE — Original Application (Ascend Laboratories, LLC)
FDA approved a generic venlafaxine product from Ascend Laboratories, LLC under Original Application (ANDA).
-
FDA approval · 2021-05-03FDA Approved: SERTRALINE HYDROCHLORIDE — Original Application (XLCare Pharmaceuticals, Inc.)
FDA approved the original application for sertraline hydrochloride generic by XLCare Pharmaceuticals, enabling a generic version to be marke…
-
FDA approval · 2021-04-19FDA Approved: FLUOXETINE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved a supplemental application for fluoxetine from Teva Pharmaceuticals USA, Inc., updating the generic's labeling under the AN…
-
CLINICAL_TRIALS trial_result · 2021-03-03Clinical Trial Update: Xenon Inhalation for Treatment of Panic Disorder [Phase 2, Phase 3]
Clinical trial update for xenon inhalation targeting panic disorder in Phase 2 and Phase 3.